nodes	percent_of_prediction	percent_of_DWPC	metapath
Memantine—SLC22A2—Cisplatin—bone cancer	0.191	0.536	CbGbCtD
Memantine—CYP2B6—Cisplatin—bone cancer	0.0993	0.278	CbGbCtD
Memantine—CYP2B6—Doxorubicin—bone cancer	0.0665	0.186	CbGbCtD
Memantine—GRIN2A—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00528	0.0474	CbGpPWpGaD
Memantine—GRIN1—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.0046	0.0413	CbGpPWpGaD
Memantine—HTR3A—SIDS Susceptibility Pathways—FEV—bone cancer	0.0046	0.0413	CbGpPWpGaD
Memantine—GRIN2B—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00449	0.0403	CbGpPWpGaD
Memantine—CYP2A6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00387	0.0348	CbGpPWpGaD
Memantine—GRIN1—SIDS Susceptibility Pathways—FEV—bone cancer	0.00383	0.0344	CbGpPWpGaD
Memantine—CYP2B6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00313	0.0281	CbGpPWpGaD
Memantine—CYP2B6—Liver X Receptor Pathway—CYP3A4—bone cancer	0.00263	0.0236	CbGpPWpGaD
Memantine—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00236	0.0212	CbGpPWpGaD
Memantine—CYP2A6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00223	0.0201	CbGpPWpGaD
Memantine—GRIN1—Mecp2 and Associated Rett Syndrome—EZH2—bone cancer	0.00214	0.0192	CbGpPWpGaD
Memantine—DRD2—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00211	0.019	CbGpPWpGaD
Memantine—CYP2A6—Xenobiotics—CYP3A4—bone cancer	0.00187	0.0168	CbGpPWpGaD
Memantine—GRIN2A—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.00183	0.0164	CbGpPWpGaD
Memantine—CYP2A6—Tamoxifen metabolism—CYP3A4—bone cancer	0.0018	0.0161	CbGpPWpGaD
Memantine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00169	0.0152	CbGpPWpGaD
Memantine—GRIN1—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.0016	0.0143	CbGpPWpGaD
Memantine—GRIN2B—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.00156	0.014	CbGpPWpGaD
Memantine—CYP2B6—Xenobiotics—CYP3A4—bone cancer	0.00151	0.0135	CbGpPWpGaD
Memantine—GRIN2A—Post NMDA receptor activation events—BRAF—bone cancer	0.00151	0.0135	CbGpPWpGaD
Memantine—CYP2A6—Fluoropyrimidine Activity—DHFR—bone cancer	0.00148	0.0133	CbGpPWpGaD
Memantine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.00139	0.0125	CbGpPWpGaD
Memantine—CYP2B6—Metapathway biotransformation—CYP4V2—bone cancer	0.00135	0.0121	CbGpPWpGaD
Memantine—GRIN1—Post NMDA receptor activation events—BRAF—bone cancer	0.00131	0.0118	CbGpPWpGaD
Memantine—CYP2A6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00128	0.0115	CbGpPWpGaD
Memantine—GRIN2B—Post NMDA receptor activation events—BRAF—bone cancer	0.00128	0.0115	CbGpPWpGaD
Memantine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.00121	0.0109	CbGpPWpGaD
Memantine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.00118	0.0106	CbGpPWpGaD
Memantine—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.00114	0.0102	CbGpPWpGaD
Memantine—GRIN2B—ErbB4 signaling events—MDM2—bone cancer	0.00112	0.0101	CbGpPWpGaD
Memantine—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.0011	0.00984	CbGpPWpGaD
Memantine—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00104	0.0093	CbGpPWpGaD
Memantine—GRIN1—BDNF signaling pathway—EIF2S1—bone cancer	0.00102	0.00916	CbGpPWpGaD
Memantine—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.00102	0.00913	CbGpPWpGaD
Memantine—GRIN2B—BDNF signaling pathway—EIF2S1—bone cancer	0.000995	0.00893	CbGpPWpGaD
Memantine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—bone cancer	0.00099	0.00889	CbGpPWpGaD
Memantine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000987	0.00886	CbGpPWpGaD
Memantine—DRD2—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000924	0.0083	CbGpPWpGaD
Memantine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000893	0.00802	CbGpPWpGaD
Memantine—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000783	0.00703	CbGpPWpGaD
Memantine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000776	0.00697	CbGpPWpGaD
Memantine—CYP2A6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000766	0.00688	CbGpPWpGaD
Memantine—HTR3A—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000645	0.00579	CbGpPWpGaD
Memantine—CYP2A6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000629	0.00565	CbGpPWpGaD
Memantine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000626	0.00562	CbGpPWpGaD
Memantine—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000618	0.00555	CbGpPWpGaD
Memantine—GRIN1—EPH-Ephrin signaling—MMP2—bone cancer	0.000587	0.00527	CbGpPWpGaD
Memantine—GRIN1—Spinal Cord Injury—CDK4—bone cancer	0.000587	0.00527	CbGpPWpGaD
Memantine—GRIN2B—EPH-Ephrin signaling—MMP2—bone cancer	0.000573	0.00514	CbGpPWpGaD
Memantine—HTR3A—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000557	0.005	CbGpPWpGaD
Memantine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000519	0.00466	CbGpPWpGaD
Memantine—GRIN1—Spinal Cord Injury—RB1—bone cancer	0.00051	0.00458	CbGpPWpGaD
Memantine—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000508	0.00456	CbGpPWpGaD
Memantine—DRD2—G alpha (i) signalling events—RGS1—bone cancer	0.000494	0.00444	CbGpPWpGaD
Memantine—DRD2—G alpha (i) signalling events—GRM4—bone cancer	0.000494	0.00444	CbGpPWpGaD
Memantine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000473	0.00425	CbGpPWpGaD
Memantine—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000467	0.00419	CbGpPWpGaD
Memantine—Infestation—Doxorubicin—bone cancer	0.000461	0.000867	CcSEcCtD
Memantine—Infestation NOS—Doxorubicin—bone cancer	0.000461	0.000867	CcSEcCtD
Memantine—Visual impairment—Methotrexate—bone cancer	0.00046	0.000866	CcSEcCtD
Memantine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000457	0.00086	CcSEcCtD
Memantine—Hypersensitivity—Cisplatin—bone cancer	0.000456	0.000858	CcSEcCtD
Memantine—Bradycardia—Epirubicin—bone cancer	0.000455	0.000856	CcSEcCtD
Memantine—Renal failure—Doxorubicin—bone cancer	0.000453	0.000852	CcSEcCtD
Memantine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000453	0.00407	CbGpPWpGaD
Memantine—Erythema multiforme—Methotrexate—bone cancer	0.000452	0.00085	CcSEcCtD
Memantine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000452	0.00085	CcSEcCtD
Memantine—Haemoglobin—Epirubicin—bone cancer	0.000449	0.000846	CcSEcCtD
Memantine—Rhinitis—Epirubicin—bone cancer	0.000448	0.000843	CcSEcCtD
Memantine—Urinary tract infection—Doxorubicin—bone cancer	0.000448	0.000843	CcSEcCtD
Memantine—Conjunctivitis—Doxorubicin—bone cancer	0.000448	0.000843	CcSEcCtD
Memantine—Haemorrhage—Epirubicin—bone cancer	0.000447	0.000841	CcSEcCtD
Memantine—Hepatitis—Epirubicin—bone cancer	0.000447	0.000841	CcSEcCtD
Memantine—Eye disorder—Methotrexate—bone cancer	0.000447	0.00084	CcSEcCtD
Memantine—Tinnitus—Methotrexate—bone cancer	0.000446	0.000838	CcSEcCtD
Memantine—Hypoaesthesia—Epirubicin—bone cancer	0.000445	0.000837	CcSEcCtD
Memantine—Asthenia—Cisplatin—bone cancer	0.000444	0.000835	CcSEcCtD
Memantine—Pharyngitis—Epirubicin—bone cancer	0.000444	0.000835	CcSEcCtD
Memantine—Cardiac disorder—Methotrexate—bone cancer	0.000443	0.000834	CcSEcCtD
Memantine—Urinary tract disorder—Epirubicin—bone cancer	0.000442	0.000831	CcSEcCtD
Memantine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000442	0.00396	CbGpPWpGaD
Memantine—GRIN1—EPH-Ephrin signaling—MMP9—bone cancer	0.000441	0.00396	CbGpPWpGaD
Memantine—Oedema peripheral—Epirubicin—bone cancer	0.000441	0.000829	CcSEcCtD
Memantine—Haematuria—Doxorubicin—bone cancer	0.000439	0.000827	CcSEcCtD
Memantine—Connective tissue disorder—Epirubicin—bone cancer	0.000439	0.000827	CcSEcCtD
Memantine—Urethral disorder—Epirubicin—bone cancer	0.000438	0.000825	CcSEcCtD
Memantine—Hepatobiliary disease—Doxorubicin—bone cancer	0.000436	0.00082	CcSEcCtD
Memantine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000435	0.00391	CbGpPWpGaD
Memantine—Epistaxis—Doxorubicin—bone cancer	0.000435	0.000818	CcSEcCtD
Memantine—Angiopathy—Methotrexate—bone cancer	0.000434	0.000816	CcSEcCtD
Memantine—Sinusitis—Doxorubicin—bone cancer	0.000432	0.000814	CcSEcCtD
Memantine—Immune system disorder—Methotrexate—bone cancer	0.000432	0.000812	CcSEcCtD
Memantine—Visual impairment—Epirubicin—bone cancer	0.000431	0.000811	CcSEcCtD
Memantine—Mediastinal disorder—Methotrexate—bone cancer	0.000431	0.00081	CcSEcCtD
Memantine—GRIN2B—EPH-Ephrin signaling—MMP9—bone cancer	0.00043	0.00386	CbGpPWpGaD
Memantine—Agranulocytosis—Doxorubicin—bone cancer	0.00043	0.000809	CcSEcCtD
Memantine—Chills—Methotrexate—bone cancer	0.000429	0.000807	CcSEcCtD
Memantine—Diarrhoea—Cisplatin—bone cancer	0.000423	0.000796	CcSEcCtD
Memantine—Erythema multiforme—Epirubicin—bone cancer	0.000423	0.000795	CcSEcCtD
Memantine—Alopecia—Methotrexate—bone cancer	0.000422	0.000794	CcSEcCtD
Memantine—Bradycardia—Doxorubicin—bone cancer	0.000421	0.000792	CcSEcCtD
Memantine—GRIN1—Spinal Cord Injury—PTGS2—bone cancer	0.00042	0.00377	CbGpPWpGaD
Memantine—Mental disorder—Methotrexate—bone cancer	0.000419	0.000788	CcSEcCtD
Memantine—Eye disorder—Epirubicin—bone cancer	0.000418	0.000786	CcSEcCtD
Memantine—Tinnitus—Epirubicin—bone cancer	0.000417	0.000784	CcSEcCtD
Memantine—Malnutrition—Methotrexate—bone cancer	0.000416	0.000783	CcSEcCtD
Memantine—Haemoglobin—Doxorubicin—bone cancer	0.000416	0.000782	CcSEcCtD
Memantine—Flushing—Epirubicin—bone cancer	0.000415	0.000781	CcSEcCtD
Memantine—Cardiac disorder—Epirubicin—bone cancer	0.000415	0.000781	CcSEcCtD
Memantine—Rhinitis—Doxorubicin—bone cancer	0.000415	0.00078	CcSEcCtD
Memantine—Hepatitis—Doxorubicin—bone cancer	0.000414	0.000778	CcSEcCtD
Memantine—Haemorrhage—Doxorubicin—bone cancer	0.000414	0.000778	CcSEcCtD
Memantine—Hypoaesthesia—Doxorubicin—bone cancer	0.000412	0.000775	CcSEcCtD
Memantine—Pharyngitis—Doxorubicin—bone cancer	0.000411	0.000773	CcSEcCtD
Memantine—Urinary tract disorder—Doxorubicin—bone cancer	0.000409	0.000769	CcSEcCtD
Memantine—Oedema peripheral—Doxorubicin—bone cancer	0.000408	0.000767	CcSEcCtD
Memantine—Dysgeusia—Methotrexate—bone cancer	0.000407	0.000766	CcSEcCtD
Memantine—Connective tissue disorder—Doxorubicin—bone cancer	0.000407	0.000765	CcSEcCtD
Memantine—Angiopathy—Epirubicin—bone cancer	0.000406	0.000763	CcSEcCtD
Memantine—Urethral disorder—Doxorubicin—bone cancer	0.000406	0.000763	CcSEcCtD
Memantine—Immune system disorder—Epirubicin—bone cancer	0.000404	0.00076	CcSEcCtD
Memantine—Mediastinal disorder—Epirubicin—bone cancer	0.000403	0.000758	CcSEcCtD
Memantine—Back pain—Methotrexate—bone cancer	0.000402	0.000757	CcSEcCtD
Memantine—Chills—Epirubicin—bone cancer	0.000401	0.000755	CcSEcCtD
Memantine—Arrhythmia—Epirubicin—bone cancer	0.000399	0.000752	CcSEcCtD
Memantine—Visual impairment—Doxorubicin—bone cancer	0.000399	0.00075	CcSEcCtD
Memantine—Alopecia—Epirubicin—bone cancer	0.000395	0.000743	CcSEcCtD
Memantine—GRIN2A—Alzheimers Disease—TP53—bone cancer	0.000395	0.00354	CbGpPWpGaD
Memantine—Vomiting—Cisplatin—bone cancer	0.000393	0.00074	CcSEcCtD
Memantine—Vision blurred—Methotrexate—bone cancer	0.000392	0.000738	CcSEcCtD
Memantine—Mental disorder—Epirubicin—bone cancer	0.000392	0.000737	CcSEcCtD
Memantine—Erythema multiforme—Doxorubicin—bone cancer	0.000391	0.000736	CcSEcCtD
Memantine—GRIN2A—Transmission across Chemical Synapses—BRAF—bone cancer	0.00039	0.00351	CbGpPWpGaD
Memantine—Rash—Cisplatin—bone cancer	0.00039	0.000734	CcSEcCtD
Memantine—Dermatitis—Cisplatin—bone cancer	0.00039	0.000733	CcSEcCtD
Memantine—Malnutrition—Epirubicin—bone cancer	0.000389	0.000732	CcSEcCtD
Memantine—Eye disorder—Doxorubicin—bone cancer	0.000387	0.000727	CcSEcCtD
Memantine—Ill-defined disorder—Methotrexate—bone cancer	0.000386	0.000726	CcSEcCtD
Memantine—Tinnitus—Doxorubicin—bone cancer	0.000386	0.000726	CcSEcCtD
Memantine—Anaemia—Methotrexate—bone cancer	0.000384	0.000723	CcSEcCtD
Memantine—Cardiac disorder—Doxorubicin—bone cancer	0.000384	0.000722	CcSEcCtD
Memantine—Flushing—Doxorubicin—bone cancer	0.000384	0.000722	CcSEcCtD
Memantine—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000384	0.00344	CbGpPWpGaD
Memantine—Flatulence—Epirubicin—bone cancer	0.000384	0.000722	CcSEcCtD
Memantine—Tension—Epirubicin—bone cancer	0.000382	0.000719	CcSEcCtD
Memantine—Dysgeusia—Epirubicin—bone cancer	0.000381	0.000717	CcSEcCtD
Memantine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.00038	0.00341	CbGpPWpGaD
Memantine—Nervousness—Epirubicin—bone cancer	0.000378	0.000711	CcSEcCtD
Memantine—Back pain—Epirubicin—bone cancer	0.000377	0.000708	CcSEcCtD
Memantine—Angiopathy—Doxorubicin—bone cancer	0.000375	0.000706	CcSEcCtD
Memantine—Malaise—Methotrexate—bone cancer	0.000375	0.000706	CcSEcCtD
Memantine—Immune system disorder—Doxorubicin—bone cancer	0.000374	0.000703	CcSEcCtD
Memantine—Vertigo—Methotrexate—bone cancer	0.000374	0.000703	CcSEcCtD
Memantine—Mediastinal disorder—Doxorubicin—bone cancer	0.000373	0.000702	CcSEcCtD
Memantine—Leukopenia—Methotrexate—bone cancer	0.000372	0.0007	CcSEcCtD
Memantine—Chills—Doxorubicin—bone cancer	0.000371	0.000698	CcSEcCtD
Memantine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.00037	0.00332	CbGpPWpGaD
Memantine—Arrhythmia—Doxorubicin—bone cancer	0.00037	0.000695	CcSEcCtD
Memantine—GRIN1—Spinal Cord Injury—MMP9—bone cancer	0.000368	0.0033	CbGpPWpGaD
Memantine—Nausea—Cisplatin—bone cancer	0.000367	0.000691	CcSEcCtD
Memantine—Vision blurred—Epirubicin—bone cancer	0.000367	0.00069	CcSEcCtD
Memantine—Alopecia—Doxorubicin—bone cancer	0.000366	0.000688	CcSEcCtD
Memantine—HTR3A—SIDS Susceptibility Pathways—JUN—bone cancer	0.000364	0.00326	CbGpPWpGaD
Memantine—Cough—Methotrexate—bone cancer	0.000363	0.000683	CcSEcCtD
Memantine—Mental disorder—Doxorubicin—bone cancer	0.000362	0.000682	CcSEcCtD
Memantine—Ill-defined disorder—Epirubicin—bone cancer	0.000361	0.00068	CcSEcCtD
Memantine—Convulsion—Methotrexate—bone cancer	0.00036	0.000678	CcSEcCtD
Memantine—Malnutrition—Doxorubicin—bone cancer	0.00036	0.000678	CcSEcCtD
Memantine—Anaemia—Epirubicin—bone cancer	0.00036	0.000677	CcSEcCtD
Memantine—Agitation—Epirubicin—bone cancer	0.000358	0.000673	CcSEcCtD
Memantine—Flatulence—Doxorubicin—bone cancer	0.000355	0.000668	CcSEcCtD
Memantine—Chest pain—Methotrexate—bone cancer	0.000354	0.000666	CcSEcCtD
Memantine—Myalgia—Methotrexate—bone cancer	0.000354	0.000666	CcSEcCtD
Memantine—Arthralgia—Methotrexate—bone cancer	0.000354	0.000666	CcSEcCtD
Memantine—Tension—Doxorubicin—bone cancer	0.000353	0.000665	CcSEcCtD
Memantine—Dysgeusia—Doxorubicin—bone cancer	0.000353	0.000664	CcSEcCtD
Memantine—Malaise—Epirubicin—bone cancer	0.000351	0.00066	CcSEcCtD
Memantine—Discomfort—Methotrexate—bone cancer	0.00035	0.000658	CcSEcCtD
Memantine—Nervousness—Doxorubicin—bone cancer	0.00035	0.000658	CcSEcCtD
Memantine—Vertigo—Epirubicin—bone cancer	0.00035	0.000658	CcSEcCtD
Memantine—Syncope—Epirubicin—bone cancer	0.000349	0.000657	CcSEcCtD
Memantine—Leukopenia—Epirubicin—bone cancer	0.000348	0.000656	CcSEcCtD
Memantine—Back pain—Doxorubicin—bone cancer	0.000348	0.000655	CcSEcCtD
Memantine—GRIN1—Alzheimers Disease—TP53—bone cancer	0.000344	0.00309	CbGpPWpGaD
Memantine—Palpitations—Epirubicin—bone cancer	0.000344	0.000647	CcSEcCtD
Memantine—Confusional state—Methotrexate—bone cancer	0.000342	0.000644	CcSEcCtD
Memantine—Loss of consciousness—Epirubicin—bone cancer	0.000342	0.000644	CcSEcCtD
Memantine—GRIN1—Transmission across Chemical Synapses—BRAF—bone cancer	0.000341	0.00306	CbGpPWpGaD
Memantine—Cough—Epirubicin—bone cancer	0.00034	0.000639	CcSEcCtD
Memantine—Vision blurred—Doxorubicin—bone cancer	0.000339	0.000639	CcSEcCtD
Memantine—Convulsion—Epirubicin—bone cancer	0.000337	0.000635	CcSEcCtD
Memantine—Infection—Methotrexate—bone cancer	0.000337	0.000635	CcSEcCtD
Memantine—Hypertension—Epirubicin—bone cancer	0.000336	0.000632	CcSEcCtD
Memantine—GRIN2B—Alzheimers Disease—TP53—bone cancer	0.000336	0.00301	CbGpPWpGaD
Memantine—CYP2A6—Biological oxidations—CYP3A4—bone cancer	0.000334	0.003	CbGpPWpGaD
Memantine—Ill-defined disorder—Doxorubicin—bone cancer	0.000334	0.000629	CcSEcCtD
Memantine—Nervous system disorder—Methotrexate—bone cancer	0.000333	0.000626	CcSEcCtD
Memantine—Anaemia—Doxorubicin—bone cancer	0.000333	0.000626	CcSEcCtD
Memantine—Thrombocytopenia—Methotrexate—bone cancer	0.000332	0.000625	CcSEcCtD
Memantine—GRIN2B—Transmission across Chemical Synapses—BRAF—bone cancer	0.000332	0.00298	CbGpPWpGaD
Memantine—Myalgia—Epirubicin—bone cancer	0.000331	0.000623	CcSEcCtD
Memantine—Chest pain—Epirubicin—bone cancer	0.000331	0.000623	CcSEcCtD
Memantine—Arthralgia—Epirubicin—bone cancer	0.000331	0.000623	CcSEcCtD
Memantine—Agitation—Doxorubicin—bone cancer	0.000331	0.000623	CcSEcCtD
Memantine—Anxiety—Epirubicin—bone cancer	0.00033	0.000621	CcSEcCtD
Memantine—CYP2A6—Fluoropyrimidine Activity—TP53—bone cancer	0.00033	0.00297	CbGpPWpGaD
Memantine—Skin disorder—Methotrexate—bone cancer	0.00033	0.00062	CcSEcCtD
Memantine—Hyperhidrosis—Methotrexate—bone cancer	0.000328	0.000617	CcSEcCtD
Memantine—Discomfort—Epirubicin—bone cancer	0.000327	0.000616	CcSEcCtD
Memantine—GRIN2A—Transmission across Chemical Synapses—MDM2—bone cancer	0.000327	0.00294	CbGpPWpGaD
Memantine—CYP2A6—NRF2 pathway—TGFBR2—bone cancer	0.000326	0.00293	CbGpPWpGaD
Memantine—CYP2A6—NRF2 pathway—GSTP1—bone cancer	0.000326	0.00293	CbGpPWpGaD
Memantine—Malaise—Doxorubicin—bone cancer	0.000325	0.000611	CcSEcCtD
Memantine—Dry mouth—Epirubicin—bone cancer	0.000324	0.00061	CcSEcCtD
Memantine—Vertigo—Doxorubicin—bone cancer	0.000324	0.000609	CcSEcCtD
Memantine—Anorexia—Methotrexate—bone cancer	0.000324	0.000609	CcSEcCtD
Memantine—Syncope—Doxorubicin—bone cancer	0.000323	0.000608	CcSEcCtD
Memantine—GRIN1—BDNF signaling pathway—JUN—bone cancer	0.000323	0.0029	CbGpPWpGaD
Memantine—Leukopenia—Doxorubicin—bone cancer	0.000322	0.000607	CcSEcCtD
Memantine—Confusional state—Epirubicin—bone cancer	0.00032	0.000603	CcSEcCtD
Memantine—Palpitations—Doxorubicin—bone cancer	0.000318	0.000599	CcSEcCtD
Memantine—Oedema—Epirubicin—bone cancer	0.000318	0.000598	CcSEcCtD
Memantine—Hypotension—Methotrexate—bone cancer	0.000317	0.000597	CcSEcCtD
Memantine—Loss of consciousness—Doxorubicin—bone cancer	0.000317	0.000596	CcSEcCtD
Memantine—Infection—Epirubicin—bone cancer	0.000316	0.000594	CcSEcCtD
Memantine—GRIN2B—BDNF signaling pathway—JUN—bone cancer	0.000314	0.00282	CbGpPWpGaD
Memantine—Cough—Doxorubicin—bone cancer	0.000314	0.000591	CcSEcCtD
Memantine—DRD2—Circadian rythm related genes—GNA11—bone cancer	0.000313	0.00281	CbGpPWpGaD
Memantine—Shock—Epirubicin—bone cancer	0.000313	0.000588	CcSEcCtD
Memantine—Convulsion—Doxorubicin—bone cancer	0.000312	0.000587	CcSEcCtD
Memantine—Nervous system disorder—Epirubicin—bone cancer	0.000312	0.000586	CcSEcCtD
Memantine—DRD2—Circadian rythm related genes—EZH2—bone cancer	0.000312	0.0028	CbGpPWpGaD
Memantine—Thrombocytopenia—Epirubicin—bone cancer	0.000311	0.000585	CcSEcCtD
Memantine—Hypertension—Doxorubicin—bone cancer	0.000311	0.000585	CcSEcCtD
Memantine—Tachycardia—Epirubicin—bone cancer	0.00031	0.000583	CcSEcCtD
Memantine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000309	0.000582	CcSEcCtD
Memantine—Skin disorder—Epirubicin—bone cancer	0.000309	0.000581	CcSEcCtD
Memantine—Hyperhidrosis—Epirubicin—bone cancer	0.000307	0.000578	CcSEcCtD
Memantine—Insomnia—Methotrexate—bone cancer	0.000307	0.000578	CcSEcCtD
Memantine—Myalgia—Doxorubicin—bone cancer	0.000307	0.000577	CcSEcCtD
Memantine—Chest pain—Doxorubicin—bone cancer	0.000307	0.000577	CcSEcCtD
Memantine—Arthralgia—Doxorubicin—bone cancer	0.000307	0.000577	CcSEcCtD
Memantine—Anxiety—Doxorubicin—bone cancer	0.000306	0.000575	CcSEcCtD
Memantine—Paraesthesia—Methotrexate—bone cancer	0.000305	0.000574	CcSEcCtD
Memantine—Discomfort—Doxorubicin—bone cancer	0.000303	0.00057	CcSEcCtD
Memantine—Anorexia—Epirubicin—bone cancer	0.000303	0.00057	CcSEcCtD
Memantine—Dyspnoea—Methotrexate—bone cancer	0.000303	0.000569	CcSEcCtD
Memantine—GRIN1—SIDS Susceptibility Pathways—JUN—bone cancer	0.000303	0.00272	CbGpPWpGaD
Memantine—Somnolence—Methotrexate—bone cancer	0.000302	0.000568	CcSEcCtD
Memantine—Dry mouth—Doxorubicin—bone cancer	0.0003	0.000564	CcSEcCtD
Memantine—DRD2—GPCR ligand binding—GRM4—bone cancer	0.000299	0.00269	CbGpPWpGaD
Memantine—GRIN2A—Neuronal System—BRAF—bone cancer	0.000299	0.00269	CbGpPWpGaD
Memantine—Dyspepsia—Methotrexate—bone cancer	0.000299	0.000562	CcSEcCtD
Memantine—GRIN1—Spinal Cord Injury—EGFR—bone cancer	0.000297	0.00267	CbGpPWpGaD
Memantine—Hypotension—Epirubicin—bone cancer	0.000297	0.000559	CcSEcCtD
Memantine—Confusional state—Doxorubicin—bone cancer	0.000296	0.000558	CcSEcCtD
Memantine—Decreased appetite—Methotrexate—bone cancer	0.000295	0.000555	CcSEcCtD
Memantine—Oedema—Doxorubicin—bone cancer	0.000294	0.000553	CcSEcCtD
Memantine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000293	0.000551	CcSEcCtD
Memantine—Fatigue—Methotrexate—bone cancer	0.000293	0.000551	CcSEcCtD
Memantine—Infection—Doxorubicin—bone cancer	0.000292	0.000549	CcSEcCtD
Memantine—Pain—Methotrexate—bone cancer	0.00029	0.000546	CcSEcCtD
Memantine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000289	0.000545	CcSEcCtD
Memantine—Shock—Doxorubicin—bone cancer	0.000289	0.000544	CcSEcCtD
Memantine—Nervous system disorder—Doxorubicin—bone cancer	0.000288	0.000542	CcSEcCtD
Memantine—Thrombocytopenia—Doxorubicin—bone cancer	0.000288	0.000541	CcSEcCtD
Memantine—Insomnia—Epirubicin—bone cancer	0.000287	0.000541	CcSEcCtD
Memantine—Tachycardia—Doxorubicin—bone cancer	0.000287	0.00054	CcSEcCtD
Memantine—CYP2A6—Biological oxidations—GSTP1—bone cancer	0.000286	0.00257	CbGpPWpGaD
Memantine—Skin disorder—Doxorubicin—bone cancer	0.000286	0.000537	CcSEcCtD
Memantine—GRIN1—Transmission across Chemical Synapses—MDM2—bone cancer	0.000285	0.00256	CbGpPWpGaD
Memantine—Paraesthesia—Epirubicin—bone cancer	0.000285	0.000537	CcSEcCtD
Memantine—Hyperhidrosis—Doxorubicin—bone cancer	0.000284	0.000535	CcSEcCtD
Memantine—Dyspnoea—Epirubicin—bone cancer	0.000283	0.000533	CcSEcCtD
Memantine—Somnolence—Epirubicin—bone cancer	0.000282	0.000531	CcSEcCtD
Memantine—Anorexia—Doxorubicin—bone cancer	0.00028	0.000527	CcSEcCtD
Memantine—Feeling abnormal—Methotrexate—bone cancer	0.00028	0.000526	CcSEcCtD
Memantine—Dyspepsia—Epirubicin—bone cancer	0.00028	0.000526	CcSEcCtD
Memantine—SLC22A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000279	0.00251	CbGpPWpGaD
Memantine—GRIN2B—Transmission across Chemical Synapses—MDM2—bone cancer	0.000278	0.0025	CbGpPWpGaD
Memantine—Gastrointestinal pain—Methotrexate—bone cancer	0.000278	0.000522	CcSEcCtD
Memantine—Decreased appetite—Epirubicin—bone cancer	0.000276	0.00052	CcSEcCtD
Memantine—Hypotension—Doxorubicin—bone cancer	0.000275	0.000517	CcSEcCtD
Memantine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000274	0.000516	CcSEcCtD
Memantine—Fatigue—Epirubicin—bone cancer	0.000274	0.000515	CcSEcCtD
Memantine—Constipation—Epirubicin—bone cancer	0.000272	0.000511	CcSEcCtD
Memantine—Pain—Epirubicin—bone cancer	0.000272	0.000511	CcSEcCtD
Memantine—CYP2B6—Biological oxidations—CYP3A4—bone cancer	0.00027	0.00242	CbGpPWpGaD
Memantine—Urticaria—Methotrexate—bone cancer	0.00027	0.000507	CcSEcCtD
Memantine—Abdominal pain—Methotrexate—bone cancer	0.000268	0.000505	CcSEcCtD
Memantine—Body temperature increased—Methotrexate—bone cancer	0.000268	0.000505	CcSEcCtD
Memantine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000268	0.000504	CcSEcCtD
Memantine—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	0.000266	0.00239	CbGpPWpGaD
Memantine—Insomnia—Doxorubicin—bone cancer	0.000266	0.0005	CcSEcCtD
Memantine—Paraesthesia—Doxorubicin—bone cancer	0.000264	0.000497	CcSEcCtD
Memantine—Dyspnoea—Doxorubicin—bone cancer	0.000262	0.000493	CcSEcCtD
Memantine—Feeling abnormal—Epirubicin—bone cancer	0.000262	0.000493	CcSEcCtD
Memantine—GRIN1—Axon guidance—MET—bone cancer	0.000262	0.00235	CbGpPWpGaD
Memantine—Somnolence—Doxorubicin—bone cancer	0.000261	0.000492	CcSEcCtD
Memantine—GRIN1—Neuronal System—BRAF—bone cancer	0.000261	0.00234	CbGpPWpGaD
Memantine—Gastrointestinal pain—Epirubicin—bone cancer	0.00026	0.000489	CcSEcCtD
Memantine—DRD2—GPCR ligand binding—GRM1—bone cancer	0.000259	0.00233	CbGpPWpGaD
Memantine—Dyspepsia—Doxorubicin—bone cancer	0.000259	0.000487	CcSEcCtD
Memantine—Decreased appetite—Doxorubicin—bone cancer	0.000256	0.000481	CcSEcCtD
Memantine—GRIN2B—Axon guidance—MET—bone cancer	0.000255	0.00229	CbGpPWpGaD
Memantine—GRIN2B—Neuronal System—BRAF—bone cancer	0.000254	0.00228	CbGpPWpGaD
Memantine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000254	0.000477	CcSEcCtD
Memantine—Fatigue—Doxorubicin—bone cancer	0.000253	0.000477	CcSEcCtD
Memantine—Urticaria—Epirubicin—bone cancer	0.000252	0.000475	CcSEcCtD
Memantine—Constipation—Doxorubicin—bone cancer	0.000251	0.000473	CcSEcCtD
Memantine—Pain—Doxorubicin—bone cancer	0.000251	0.000473	CcSEcCtD
Memantine—Abdominal pain—Epirubicin—bone cancer	0.000251	0.000472	CcSEcCtD
Memantine—Body temperature increased—Epirubicin—bone cancer	0.000251	0.000472	CcSEcCtD
Memantine—GRIN2A—Neuronal System—MDM2—bone cancer	0.000251	0.00225	CbGpPWpGaD
Memantine—Hypersensitivity—Methotrexate—bone cancer	0.00025	0.000471	CcSEcCtD
Memantine—GRIN1—Spinal Cord Injury—TP53—bone cancer	0.00025	0.00224	CbGpPWpGaD
Memantine—Asthenia—Methotrexate—bone cancer	0.000244	0.000458	CcSEcCtD
Memantine—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000243	0.00218	CbGpPWpGaD
Memantine—Feeling abnormal—Doxorubicin—bone cancer	0.000242	0.000456	CcSEcCtD
Memantine—SLC22A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000241	0.00216	CbGpPWpGaD
Memantine—Gastrointestinal pain—Doxorubicin—bone cancer	0.00024	0.000452	CcSEcCtD
Memantine—Pruritus—Methotrexate—bone cancer	0.00024	0.000452	CcSEcCtD
Memantine—Hypersensitivity—Epirubicin—bone cancer	0.000234	0.00044	CcSEcCtD
Memantine—Urticaria—Doxorubicin—bone cancer	0.000234	0.000439	CcSEcCtD
Memantine—Abdominal pain—Doxorubicin—bone cancer	0.000232	0.000437	CcSEcCtD
Memantine—Body temperature increased—Doxorubicin—bone cancer	0.000232	0.000437	CcSEcCtD
Memantine—Diarrhoea—Methotrexate—bone cancer	0.000232	0.000437	CcSEcCtD
Memantine—CYP2B6—Biological oxidations—GSTP1—bone cancer	0.000231	0.00207	CbGpPWpGaD
Memantine—Asthenia—Epirubicin—bone cancer	0.000228	0.000429	CcSEcCtD
Memantine—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	0.000227	0.00204	CbGpPWpGaD
Memantine—Pruritus—Epirubicin—bone cancer	0.000225	0.000423	CcSEcCtD
Memantine—Dizziness—Methotrexate—bone cancer	0.000224	0.000422	CcSEcCtD
Memantine—GRIN1—Neuronal System—MDM2—bone cancer	0.000219	0.00196	CbGpPWpGaD
Memantine—SLC22A2—Metabolism—NDUFA12—bone cancer	0.000218	0.00196	CbGpPWpGaD
Memantine—GRIN1—Axon guidance—MMP2—bone cancer	0.000218	0.00196	CbGpPWpGaD
Memantine—Diarrhoea—Epirubicin—bone cancer	0.000217	0.000409	CcSEcCtD
Memantine—Hypersensitivity—Doxorubicin—bone cancer	0.000217	0.000407	CcSEcCtD
Memantine—Vomiting—Methotrexate—bone cancer	0.000216	0.000406	CcSEcCtD
Memantine—Rash—Methotrexate—bone cancer	0.000214	0.000403	CcSEcCtD
Memantine—Dermatitis—Methotrexate—bone cancer	0.000214	0.000402	CcSEcCtD
Memantine—GRIN2B—Neuronal System—MDM2—bone cancer	0.000213	0.00191	CbGpPWpGaD
Memantine—GRIN2B—Axon guidance—MMP2—bone cancer	0.000213	0.00191	CbGpPWpGaD
Memantine—Headache—Methotrexate—bone cancer	0.000213	0.0004	CcSEcCtD
Memantine—Asthenia—Doxorubicin—bone cancer	0.000211	0.000397	CcSEcCtD
Memantine—Dizziness—Epirubicin—bone cancer	0.00021	0.000395	CcSEcCtD
Memantine—Pruritus—Doxorubicin—bone cancer	0.000208	0.000391	CcSEcCtD
Memantine—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000204	0.00183	CbGpPWpGaD
Memantine—Vomiting—Epirubicin—bone cancer	0.000202	0.00038	CcSEcCtD
Memantine—Nausea—Methotrexate—bone cancer	0.000202	0.000379	CcSEcCtD
Memantine—Diarrhoea—Doxorubicin—bone cancer	0.000201	0.000378	CcSEcCtD
Memantine—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000201	0.0018	CbGpPWpGaD
Memantine—CYP2A6—Metabolism—NDUFA12—bone cancer	0.0002	0.0018	CbGpPWpGaD
Memantine—Rash—Epirubicin—bone cancer	0.0002	0.000377	CcSEcCtD
Memantine—Dermatitis—Epirubicin—bone cancer	0.0002	0.000377	CcSEcCtD
Memantine—Headache—Epirubicin—bone cancer	0.000199	0.000374	CcSEcCtD
Memantine—Dizziness—Doxorubicin—bone cancer	0.000194	0.000366	CcSEcCtD
Memantine—Nausea—Epirubicin—bone cancer	0.000189	0.000355	CcSEcCtD
Memantine—Vomiting—Doxorubicin—bone cancer	0.000187	0.000352	CcSEcCtD
Memantine—GRIN1—Developmental Biology—CDK4—bone cancer	0.000187	0.00168	CbGpPWpGaD
Memantine—GRIN1—Developmental Biology—MET—bone cancer	0.000187	0.00168	CbGpPWpGaD
Memantine—Rash—Doxorubicin—bone cancer	0.000185	0.000349	CcSEcCtD
Memantine—Dermatitis—Doxorubicin—bone cancer	0.000185	0.000348	CcSEcCtD
Memantine—Headache—Doxorubicin—bone cancer	0.000184	0.000346	CcSEcCtD
Memantine—DRD2—GPCR ligand binding—SMO—bone cancer	0.000183	0.00164	CbGpPWpGaD
Memantine—GRIN2B—Developmental Biology—CDK4—bone cancer	0.000182	0.00163	CbGpPWpGaD
Memantine—GRIN2B—Developmental Biology—MET—bone cancer	0.000182	0.00163	CbGpPWpGaD
Memantine—SLC22A2—Metabolism—NT5C3A—bone cancer	0.000181	0.00162	CbGpPWpGaD
Memantine—SLC22A2—Transmission across Chemical Synapses—BRAF—bone cancer	0.000177	0.00159	CbGpPWpGaD
Memantine—DRD2—Circadian rythm related genes—CDK4—bone cancer	0.000176	0.00158	CbGpPWpGaD
Memantine—Nausea—Doxorubicin—bone cancer	0.000175	0.000328	CcSEcCtD
Memantine—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000174	0.00156	CbGpPWpGaD
Memantine—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.000172	0.00154	CbGpPWpGaD
Memantine—DRD2—GPCR downstream signaling—GRM4—bone cancer	0.000169	0.00152	CbGpPWpGaD
Memantine—DRD2—GPCR downstream signaling—RGS1—bone cancer	0.000169	0.00152	CbGpPWpGaD
Memantine—CYP2A6—Metabolism—NT5C3A—bone cancer	0.000166	0.00149	CbGpPWpGaD
Memantine—GRIN1—Axon guidance—MMP9—bone cancer	0.000164	0.00147	CbGpPWpGaD
Memantine—CYP2B6—Metabolism—NDUFA12—bone cancer	0.000162	0.00145	CbGpPWpGaD
Memantine—GRIN2B—Axon guidance—MMP9—bone cancer	0.00016	0.00144	CbGpPWpGaD
Memantine—GRIN1—Developmental Biology—MMP2—bone cancer	0.000156	0.0014	CbGpPWpGaD
Memantine—DRD2—Signaling by GPCR—RGS1—bone cancer	0.000154	0.00138	CbGpPWpGaD
Memantine—DRD2—Signaling by GPCR—GRM4—bone cancer	0.000154	0.00138	CbGpPWpGaD
Memantine—GRIN2B—Developmental Biology—MMP2—bone cancer	0.000152	0.00136	CbGpPWpGaD
Memantine—SLC22A2—Transmission across Chemical Synapses—MDM2—bone cancer	0.000148	0.00133	CbGpPWpGaD
Memantine—DRD2—GPCR downstream signaling—GRM1—bone cancer	0.000147	0.00132	CbGpPWpGaD
Memantine—SLC22A2—Neuronal System—BRAF—bone cancer	0.000136	0.00122	CbGpPWpGaD
Memantine—CYP2B6—Metabolism—NT5C3A—bone cancer	0.000134	0.0012	CbGpPWpGaD
Memantine—DRD2—Signaling by GPCR—GRM1—bone cancer	0.000133	0.0012	CbGpPWpGaD
Memantine—GRIN1—Axon guidance—EGFR—bone cancer	0.000133	0.00119	CbGpPWpGaD
Memantine—GRIN2B—Axon guidance—EGFR—bone cancer	0.000129	0.00116	CbGpPWpGaD
Memantine—CYP2C19—Metabolism—NDUFA12—bone cancer	0.000122	0.0011	CbGpPWpGaD
Memantine—GRIN1—Developmental Biology—MMP9—bone cancer	0.000117	0.00105	CbGpPWpGaD
Memantine—GRIN2B—Developmental Biology—MMP9—bone cancer	0.000114	0.00102	CbGpPWpGaD
Memantine—SLC22A2—Neuronal System—MDM2—bone cancer	0.000114	0.00102	CbGpPWpGaD
Memantine—DRD2—Circadian rythm related genes—JUN—bone cancer	0.000113	0.00102	CbGpPWpGaD
Memantine—CYP2C19—Metabolism—NT5C3A—bone cancer	0.000101	0.000909	CbGpPWpGaD
Memantine—GRIN1—Developmental Biology—EGFR—bone cancer	9.46e-05	0.000849	CbGpPWpGaD
Memantine—DRD2—GPCR downstream signaling—GNA11—bone cancer	9.45e-05	0.000848	CbGpPWpGaD
Memantine—DRD2—Signaling by GPCR—SMO—bone cancer	9.38e-05	0.000842	CbGpPWpGaD
Memantine—GRIN2B—Developmental Biology—EGFR—bone cancer	9.22e-05	0.000828	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—GRM4—bone cancer	9.07e-05	0.000815	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—RGS1—bone cancer	9.07e-05	0.000815	CbGpPWpGaD
Memantine—DRD2—Signaling by GPCR—GNA11—bone cancer	8.58e-05	0.00077	CbGpPWpGaD
Memantine—DRD2—GPCR downstream signaling—IL3—bone cancer	8.57e-05	0.000769	CbGpPWpGaD
Memantine—SLC22A2—Metabolism—ENO2—bone cancer	7.92e-05	0.000711	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—GRM1—bone cancer	7.87e-05	0.000706	CbGpPWpGaD
Memantine—DRD2—Signaling by GPCR—IL3—bone cancer	7.78e-05	0.000698	CbGpPWpGaD
Memantine—DRD2—Circadian rythm related genes—TP53—bone cancer	7.48e-05	0.000672	CbGpPWpGaD
Memantine—SLC22A2—Metabolism—DHFR—bone cancer	7.35e-05	0.00066	CbGpPWpGaD
Memantine—CYP2A6—Metabolism—ENO2—bone cancer	7.27e-05	0.000653	CbGpPWpGaD
Memantine—SLC22A2—Metabolism—GNA11—bone cancer	6.87e-05	0.000617	CbGpPWpGaD
Memantine—CYP2A6—Metabolism—DHFR—bone cancer	6.75e-05	0.000606	CbGpPWpGaD
Memantine—CYP2A6—Metabolism—GNA11—bone cancer	6.31e-05	0.000566	CbGpPWpGaD
Memantine—SLC22A2—Metabolism—CYP3A4—bone cancer	6.23e-05	0.000559	CbGpPWpGaD
Memantine—CYP2B6—Metabolism—ENO2—bone cancer	5.87e-05	0.000527	CbGpPWpGaD
Memantine—CYP2A6—Metabolism—CYP3A4—bone cancer	5.72e-05	0.000513	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—SMO—bone cancer	5.54e-05	0.000498	CbGpPWpGaD
Memantine—CYP2B6—Metabolism—DHFR—bone cancer	5.44e-05	0.000489	CbGpPWpGaD
Memantine—SLC22A2—Metabolism—GSTP1—bone cancer	5.33e-05	0.000478	CbGpPWpGaD
Memantine—CYP2B6—Metabolism—GNA11—bone cancer	5.09e-05	0.000457	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—GNA11—bone cancer	5.07e-05	0.000455	CbGpPWpGaD
Memantine—CYP2A6—Metabolism—GSTP1—bone cancer	4.89e-05	0.000439	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—ATF1—bone cancer	4.71e-05	0.000423	CbGpPWpGaD
Memantine—CYP2B6—Metabolism—CYP3A4—bone cancer	4.61e-05	0.000414	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—IL3—bone cancer	4.6e-05	0.000413	CbGpPWpGaD
Memantine—CYP2C19—Metabolism—ENO2—bone cancer	4.43e-05	0.000398	CbGpPWpGaD
Memantine—CYP2C19—Metabolism—DHFR—bone cancer	4.11e-05	0.000369	CbGpPWpGaD
Memantine—CYP2B6—Metabolism—GSTP1—bone cancer	3.94e-05	0.000354	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—TGFBR2—bone cancer	3.93e-05	0.000353	CbGpPWpGaD
Memantine—CYP2C19—Metabolism—GNA11—bone cancer	3.84e-05	0.000345	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—IGF1R—bone cancer	3.7e-05	0.000332	CbGpPWpGaD
Memantine—CYP2C19—Metabolism—CYP3A4—bone cancer	3.49e-05	0.000313	CbGpPWpGaD
Memantine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.47e-05	0.000311	CbGpPWpGaD
Memantine—CYP2C19—Metabolism—GSTP1—bone cancer	2.98e-05	0.000268	CbGpPWpGaD
Memantine—SLC22A2—Metabolism—PTGS2—bone cancer	2.76e-05	0.000248	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—KIT—bone cancer	2.68e-05	0.000241	CbGpPWpGaD
Memantine—CYP2A6—Metabolism—PTGS2—bone cancer	2.53e-05	0.000227	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—BRAF—bone cancer	2.52e-05	0.000226	CbGpPWpGaD
Memantine—DRD2—Signaling by GPCR—EGFR—bone cancer	2.44e-05	0.000219	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—MDM2—bone cancer	2.11e-05	0.00019	CbGpPWpGaD
Memantine—CYP2B6—Metabolism—PTGS2—bone cancer	2.04e-05	0.000183	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—JUN—bone cancer	1.84e-05	0.000165	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—MMP9—bone cancer	1.79e-05	0.00016	CbGpPWpGaD
Memantine—CYP2C19—Metabolism—PTGS2—bone cancer	1.54e-05	0.000139	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—EGFR—bone cancer	1.44e-05	0.00013	CbGpPWpGaD
Memantine—DRD2—Signaling Pathways—TP53—bone cancer	1.21e-05	0.000109	CbGpPWpGaD
